Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on cell and exosome-based therapeutics for rare diseases, will release its Q2 2025 financial results on August 13, 2025, after market close. The company will host a conference call at 4:30 p.m. ET the same day.
Capricor's lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne Muscular Dystrophy (DMD). The company has partnered with Nippon Shinyaku for exclusive commercialization rights in the US and Japan. Additionally, Capricor is developing its proprietary StealthX™ platform for targeted delivery of therapeutics.
Capricor Therapeutics (NASDAQ: CAPR), un'azienda biotecnologica specializzata in terapie a base di cellule ed esosomi per malattie rare, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 il 13 agosto 2025, dopo la chiusura del mercato. La società terrà una conference call lo stesso giorno alle 16:30 ET.
Il principale candidato terapeutico di Capricor, Deramiocel, è una terapia cellulare allogenica derivata dal cuore in fase avanzata di sviluppo per la distrofia muscolare di Duchenne (DMD). L'azienda ha stretto una partnership con Nippon Shinyaku per i diritti esclusivi di commercializzazione negli Stati Uniti e in Giappone. Inoltre, Capricor sta sviluppando la propria piattaforma proprietaria StealthX™ per la somministrazione mirata di terapie.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en terapias basadas en células y exosomas para enfermedades raras, publicará sus resultados financieros del segundo trimestre de 2025 el 13 de agosto de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia el mismo día a las 4:30 p.m. ET.
El principal candidato a producto de Capricor, Deramiocel, es una terapia celular alogénica derivada del corazón en etapa avanzada para la distrofia muscular de Duchenne (DMD). La empresa ha establecido una alianza con Nippon Shinyaku para los derechos exclusivos de comercialización en EE. UU. y Japón. Además, Capricor está desarrollando su plataforma propia StealthX™ para la administración dirigida de terapias.
Capricor Therapeutics (NASDAQ: CAPR)는 희귀 질환을 위한 세포 및 엑소좀 기반 치료제를 개발하는 생명공학 회사로, 2025년 8월 13일 장 마감 후 2025년 2분기 재무 결과를 발표할 예정입니다. 같은 날 오후 4시 30분(동부 시간)에 컨퍼런스 콜을 진행합니다.
Capricor의 주요 제품 후보인 Deramiocel은 뒤센 근이영양증(DMD)을 위한 후기 단계 개발 중인 동종 심장 유래 세포 치료제입니다. 회사는 미국과 일본에서 독점 상업화 권리를 위해 Nippon Shinyaku와 파트너십을 맺었습니다. 또한 Capricor는 치료제의 표적 전달을 위한 독자적인 StealthX™ 플랫폼을 개발 중입니다.
Capricor Therapeutics (NASDAQ : CAPR), une entreprise de biotechnologie spécialisée dans les thérapies à base de cellules et d’exosomes pour les maladies rares, publiera ses résultats financiers du deuxième trimestre 2025 le 13 août 2025, après la clôture des marchés. La société tiendra une conférence téléphonique le même jour à 16h30 ET.
Le principal candidat médicament de Capricor, Deramiocel, est une thérapie cellulaire allogénique dérivée du cœur en phase avancée de développement pour la dystrophie musculaire de Duchenne (DMD). L’entreprise a conclu un partenariat avec Nippon Shinyaku pour les droits exclusifs de commercialisation aux États-Unis et au Japon. De plus, Capricor développe sa plateforme propriétaire StealthX™ pour la délivrance ciblée de traitements.
Capricor Therapeutics (NASDAQ: CAPR), ein Biotechnologieunternehmen, das sich auf zell- und exosomenbasierte Therapien für seltene Krankheiten spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am 13. August 2025 nach Börsenschluss veröffentlichen. Am selben Tag findet um 16:30 Uhr ET eine Telefonkonferenz statt.
Der führende Produktkandidat von Capricor, Deramiocel, ist eine allogene, herzabgeleitete Zelltherapie in der späten Entwicklungsphase für die Duchenne-Muskeldystrophie (DMD). Das Unternehmen hat eine Partnerschaft mit Nippon Shinyaku für exklusive Vermarktungsrechte in den USA und Japan geschlossen. Darüber hinaus entwickelt Capricor seine proprietäre StealthX™-Plattform für die gezielte Verabreichung von Therapeutika.
- None.
- None.
– Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET –
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day.
| Title: | Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Wednesday, August 13, 2025 |
| Time: | 4:30 p.m. ET |
| Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 90328 Participants can use the guest dial-in numbers above and be answered by an operator, or click the Call me™ link for instant telephone access to the event. |
| Webcast: | Webcast – Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown Deramiocel to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. Deramiocel is currently in late-stage development for the treatment of Duchenne Muscular Dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on May 14, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
When will Capricor Therapeutics (CAPR) report Q2 2025 earnings?
How can investors access Capricor's Q2 2025 earnings call?
What is Capricor's main product candidate?
Who are Capricor's commercial partners for Deramiocel?
What is Capricor's StealthX platform?
